Shanshan Lang

Title: Shanshan Lang: Innovator in CAR T Cell Therapy

Introduction

Shanshan Lang is a prominent inventor based in San Mateo, CA (US). She has made significant contributions to the field of immunotherapy, particularly in the development of innovative treatments for cancer. Her work focuses on enhancing the efficacy of chimeric antigen receptor (CAR) T cell therapies.

Latest Patents

Shanshan Lang holds a patent for the "Protease-activating CD45-gate CAR." This invention features a reversibly gated effector polypeptide that includes an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide with an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. The patent also encompasses nucleic acids, including vectors and expression vectors that encode the protease-activating CD45-gate CAR. Furthermore, it describes methods of treatment for various conditions, including different forms of cancer, by administering immune cells such as T cells that express the nucleic acids. The CD45 gate is designed to inhibit activation of the CAR until it is exposed to a specific protease, which can cleave the linker and relieve the inhibition.

Career Highlights

Throughout her career, Shanshan Lang has worked with leading companies in the biotechnology sector. Notably, she has been associated with Allogene Therapeutics, Inc. and Pfizer Corporation. Her experience in these organizations has allowed her to contribute to groundbreaking advancements in cancer treatment.

Collaborations

Shanshan has collaborated with notable professionals in her field, including Thomas John Van Blarcom and Michael Thomas Bethune. These collaborations have further enriched her research and development efforts.

Conclusion

Shanshan Lang's innovative work in CAR T cell therapy exemplifies her commitment to advancing cancer treatment. Her patent for the protease-activating CD45-gate CAR represents a significant step forward in immunotherapy.